ALMS Alumis10.50+1.03 (+10.9%)
ALMS Alumis10.20-11.61 (-53.2%)
Premarket Decliner
ALMS Alumis21.81-0.57-2.6%
Premarket:9.59-12.22 (-56.0%)
Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)
Globe NewswireTue, 1-Sep 7:30 AM
ALMS Alumis22.52-1.65 (-6.8%)
ALMS Alumis23.85+0.99 (+4.3%)
ALMS Alumis25.14+0.26 (+1.1%)